ADAPTIN BIO, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ADAPTIN BIO, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.17M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($3.12M) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($85.6K) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($27.8K) | Apr 1, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.41M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($2.57M) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($85.6K) | Apr 15, 2025 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.77M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $1.82M | Apr 1, 2026 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.78M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($649.3K) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($81.0K) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($304) | Apr 1, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $619.2K | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $239.4K | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $380 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $500 | Apr 1, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.11M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $4.34M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | $113.3K | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | $27.8K | Apr 1, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.49M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($4.10M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2023 | ($977.6K) | Apr 1, 2026 |
| FY2024 | Dec 31, 2022 | ($27.3K) | Apr 15, 2025 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.29M) | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | ($4.12M) | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | ($113.4K) | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | ($27.8K) | Apr 1, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $459.2K | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | $34.1K | Apr 1, 2026 |
| FY2023 | Dec 31, 2023 | $380 | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $500 | Apr 1, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 8.66M | Apr 1, 2026 |
| FY2025 | Dec 31, 2024 | 3.25M | Apr 1, 2026 |
| FY2024 | Dec 31, 2023 | 5.00M | Apr 15, 2025 |
| FY2023 | Dec 31, 2022 | 5.00M | Apr 1, 2024 |